• Logo
  • SBMUJournals

Comparing Different Non-invasive Methods in Assessment of the Effects of Curcumin on Hepatic Fibrosis in Patients with Non-alcoholic Fatty Liver Disease

Saeede Saadati, Azita Hekmatdoost, Behzad Hatami, Asieh Mansour, Zahra Yari, Mehdi Hedayati, Amir Sadeghi
37

Views

PDF

Abstract

.


Keywords

Fibrosis; Fibroscan;non-invasive marker plan; fatty liver

References

Aron‐Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non‐alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection. 2013;19(4):338-48.

Juan Pablo Arab, Marco Arrese, and Michael Trauner. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annu. Rev. Pathol. Mech. Dis. 2018. 13:321–50.

Robert W.Hu, Elizabeth J.carey, Keith D.Lindor, James H. Tabibian. Curcumin in hepatobiliary disease: Pharmacotherapeutic properties and emerging potential clinical applications. Concise Review. Annals of hepatology : 2017;16(6): 835-841.

Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. Curcumin and liver disease: fromchemistry to medicine. Comprehensive Reviews in Food Science and Food Safety. 2014;13(1):62-77.

Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. The molecular targets and therapeutic uses of curcumin in health and disease: Springer; 2007. p. 1-75.

B.A. Riccardo, S. Riccardo, N. Salvatore, A. Michele, S. Andrea, M.A. Maria and et,al. The role of curcumin in liver diseases. Arch Med Sci (2017).

Youcai Tang. Curcumin Targets Multiple Pathways to Halt Hepatic Stellate Cell Activation: Updated Mechanisms In Vitro and In Vivo. Review Ariticle. DOI 10.1007/s10620-014-3487-6.

Tang Y. Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo. Digestive diseases and sciences. 2015;60(6):1554-64.

Elliot B. Tapper, Neil Sengupta, M.G MyriamHunink, NezamH.Afdhal, Michelle Lia. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol advance online publication, 25 August 2015; doi:1 0.1038/ajg.2015.24.

Williams R, Aspinall R, Bellis M et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014; 384: 1953– 97.

Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of Non‐alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo‐controlled Trial. Phytotherapy Research. 2016.

Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin lowers serum lipids and uric acid in subjects with non-alcoholic fatty liver disease: A randomized controlled trial. Journal of cardiovascular pharmacology. 2016.

S-J. Jekal, B. W. Min and Ho Park. Protective Effects of Curcumin on CCl4-Induced Hepatic Fibrosis with High Fat Diet in C57BL/6 Mice. Korean J Clin Lab Sci 2015; 47(4): 251-258.

P.Angulo,J.M.Hui,G.Marchesinietal.,“TheNAFLDfibrosis score: a noninvasive system that identifies liver fibrosis in patientswithNAFLD,”Hepatology,vol.45,no.4,pp.846–854, 2007.

A.Vallet-Pichard, V.Mallet, B.Nalpaset al., “FIB-4: an inexpensiveandaccuratemarkeroffibrosisinHCVinfection. Comparisonwithliverbiopsyandfibrotest,”Hepatology,vol.46, no.1,pp.32–36,2007.

S. A. Harrison, D. Oliver, H. L. Arnold, S. Gogia, and B. A. Neuschwander-Tetri,“Developmentandvalidationofa simple NAFLDclinicalscoringsystemfoidentifyingpatientswithout advanceddisease,”Gut,vol.57,no.10,pp.1441–1447,2008.

P. Cal`es, F. Lain´e, J. Boursier et al., “Comparison of blood tests for liver fibrosis specific or not to NAFLD,” Journal of Hepatology,vol.50,no.1,pp.165–173,2009.

Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol. 2013;167(4):1109-17.

Yilmaz Y, Yesil A, Gerin F, Ergelen R, Akin H, Celikel ÇA, et al. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scandinavian journal of gastroenterology. 2014;49(5):611-6.

Lédinghen V, Vergniol J, Foucher J, Merrouche W, Bail B. Non‐invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver International. 2012;32(6):911-8.

W. Sun, H. Cui, N. Li, Y. Wei, Sh. Lai, Yang Yang and et.al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD scoreforpredictionofadvanced fibrosisinadultpatientswith non-alcoholic fatty liver disease: A meta-analysis study. Hepatology Research 2016.

Eduardo Vilar-Gomez, Luis Calzadilla-Bertot, Scott L. Friedman, BienvenidoGra-Oramas, Licet Gonzalez-Fabian, SachaLazo-del and et.al. Serum biomarkers can predict a change in liver fibrosis one year after lifestyle intervention for biopsy-proven NASH. doi: 10.1111/liv.13480.




DOI: https://doi.org/10.22037/ghfbb.v0i0.1435